Relapse risk after Discontinuation of Antidepressants during Pregnancy (R-DAP study)
怀孕期间停用抗抑郁药后复发的风险(R-DAP 研究)
基本信息
- 批准号:10569044
- 负责人:
- 金额:$ 55.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-03-02 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAntidepressive AgentsAnxiety DisordersBipolar DisorderBirthChildConceptionsDecision MakingDepressive disorderEmotionsEndocrineEventExposure toFathersFemaleFetal DevelopmentFetusGeneral PopulationGeneticGenetic Predisposition to DiseaseGenetic studyGoalsHealthImmuneInvestigationLifeLong-Term EffectsMental DepressionMental HealthMental disordersMood DisordersMoodsMothersOutcomeOutpatientsPerinatalPharmaceutical PreparationsPhysiologyPopulationPostpartum PeriodPregnancyPregnant WomenProcessPsychiatric therapeutic procedureRelapseReportingResidual stateResourcesRiskRisk FactorsRisk ReductionSample SizeSamplingSchizophreniaSelf-Injurious BehaviorSeveritiesSiblingsSleep DeprivationSuicideSuicide attemptTimeWomanWorkagedantidepressant effectgenetic informationhealth of the motherin uterointerestmaternal depressionmenoffspringperinatal periodperipartum depressionpharmacologicpolygenic risk scorepopulation basedpredictive modelingprenatal exposurerelapse riskreproductivesecondary outcometoolunborn child
项目摘要
Project Summary
Over the past decades, the use of antidepressants (ADs) as first-line treatment for both depressive and anxiety
disorders has increased exponentially, with females in their reproductive years using ADs twice as often as men.
Prior to conception or during pregnancy, approximately 50% of women on ADs (200,000 pregnant women in the
US each year) decide to discontinue their medication. While the wish to avoid in utero AD exposure to the fetus
is understandable, discontinuation of medication might lead to relapse, which can have a profound negative
impact on the health of mother and child. Unfortunately, general information on relapse risks after AD
discontinuation cannot be used during pregnancy and the postpartum period given the enormous changes in
physiology and emotion. Further, women discontinue AD prior to or during pregnancy regardless of their mood
stability, which has an impact on relapse risk. Only three small studies in highly selected populations have
investigated relapse risks during pregnancy and not a single study on AD discontinuation during pregnancy has
investigated the relapse risk postpartum.
This study will quantify the relapse risk during pregnancy and postpartum after AD discontinuation, for
the first time, in a large and representative population sample. We will use the unique Danish national longitudinal
registers covering medication use since 1995 in the entire female population giving birth aged 15-49 years
(N=1,098,137). With our sample size, we will be able to identify both pregnancy specific and non-pregnancy
specific risk factors for relapse and timing to relapse. We will determine to which extent the perinatal period is
different in terms of relapse risks after AD discontinuation compared to other periods in a woman’s life. In
addition, we will explore if women with high genetic susceptibility for mood-disorders are more vulnerable for
relapse after AD discontinuation. In our last aim we will determine the long-term effects (up to 24 years) of
maternal relapse during pregnancy and the postpartum period on the offspring. We will conduct a sibling
comparison, in which we compare the health outcomes in children exposed to maternal relapse to their siblings
not exposed to maternal relapse in the perinatal period. We will explore if polygenic risk scores of the children
influence the association between their exposure to maternal relapse and their long-term psychiatric outcome,
considering in utero exposure to AD medication.
项目摘要
在过去的几十年里,使用抗抑郁药(ADS)作为抑郁症和焦虑症的一线治疗
疾病呈指数级增长,处于生育年龄段的女性使用广告的频率是男性的两倍。
在怀孕前或怀孕期间,约50%的妇女服用ADS(美国
美国)决定停止他们的药物治疗。虽然希望避免在子宫内暴露于AD胎儿
可以理解的是,停药可能会导致复发,这可能会产生深远的负面影响
对母婴健康的影响。不幸的是,AD后复发风险的一般信息
停药不能在怀孕期间和产后使用,因为
生理和情绪。此外,女性在怀孕前或怀孕期间停止服用AD,无论她们的情绪如何
稳定性,这对复发风险有影响。只有三项在高度选择的人群中进行的小规模研究
研究了怀孕期间的复发风险,没有一项关于怀孕期间停止使用AD的研究
调查产后复发风险。
这项研究将量化AD停药后孕期和产后的复发风险,
第一次,在一个大而有代表性的人口样本中。我们将使用独一无二的丹麦民族纵向
自1995年以来在15-49岁分娩的所有女性人口中使用药物的登记
(n=1,098,137)。根据我们的样本大小,我们将能够识别特定于怀孕和非怀孕的
复发的具体风险因素和复发的时机。我们将确定围产期的程度
与女性生活中的其他时期相比,停用AD后的复发风险有所不同。在……里面
此外,我们将探索情绪障碍遗传易感性高的女性是否更容易患上
AD停药后复发。在我们的最后一个目标中,我们将确定长期影响(长达24年)
母亲在怀孕期间和产后对后代的复发。我们将举行一次兄弟会
比较,我们比较母亲复发的儿童与他们的兄弟姐妹的健康结果
在围产期不暴露于母体复发。我们将探讨儿童的多基因风险评分
影响她们接触母亲复发和她们的长期精神结果之间的联系,
考虑在子宫内暴露于AD药物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Veerle Bergink其他文献
Veerle Bergink的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Veerle Bergink', 18)}}的其他基金
The impact of prenatal maternal infection and inflammation on human brain development and psychopathology during adolescence
产前母体感染和炎症对青春期人脑发育和精神病理学的影响
- 批准号:
10296635 - 财政年份:2021
- 资助金额:
$ 55.2万 - 项目类别:
The impact of prenatal maternal infection and inflammation on human brain development and psychopathology during adolescence
产前母体感染和炎症对青春期人脑发育和精神病理学的影响
- 批准号:
10640239 - 财政年份:2021
- 资助金额:
$ 55.2万 - 项目类别:
The impact of prenatal maternal infection and inflammation on human brain development and psychopathology during adolescence
产前母体感染和炎症对青春期人脑发育和精神病理学的影响
- 批准号:
10468261 - 财政年份:2021
- 资助金额:
$ 55.2万 - 项目类别:
Relapse risk after Discontinuation of Antidepressants during Pregnancy (R-DAP study)
怀孕期间停用抗抑郁药后复发的风险(R-DAP 研究)
- 批准号:
10117285 - 财政年份:2020
- 资助金额:
$ 55.2万 - 项目类别:
EXPOSURE TO TETRACYCLINE ANTIBIOTICS AND THE POTENTIAL PROTECTIVE EFFECT ON SCHIZOPHRENIA RISK.
接触四环素抗生素及其对精神分裂症风险的潜在保护作用。
- 批准号:
10039207 - 财政年份:2020
- 资助金额:
$ 55.2万 - 项目类别:
Relapse risk after Discontinuation of Antidepressants during Pregnancy (R-DAP study)
怀孕期间停用抗抑郁药后复发的风险(R-DAP 研究)
- 批准号:
10334499 - 财政年份:2020
- 资助金额:
$ 55.2万 - 项目类别:
4:4 Investigation of opioid exposure and neurodevelopment (iOPEN)
4:4 阿片类药物暴露和神经发育的调查 (iOPEN)
- 批准号:
9899554 - 财政年份:2019
- 资助金额:
$ 55.2万 - 项目类别:
4:4 Investigation of opioid exposure and neurodevelopment (iOPEN)
4:4 阿片类药物暴露和神经发育的调查 (iOPEN)
- 批准号:
10020516 - 财政年份:2019
- 资助金额:
$ 55.2万 - 项目类别:
4:4 Investigation of opioid exposure and neurodevelopment (iOPEN)
4:4 阿片类药物暴露和神经发育的调查 (iOPEN)
- 批准号:
10321798 - 财政年份:2019
- 资助金额:
$ 55.2万 - 项目类别: